RJA
CRBU icon

Raymond James & Associates’s Caribou Biosciences CRBU Stock Holding History

Raymond James & Associates’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$21.6K Sell
11,000
-81,073
-88% -$166K ﹤0.01% 3939
2024
Q2 		$151K Sell
92,073
-9,078
-9% -$29K ﹤0.01% 3664
2024
Q1 		$520K Sell
101,151
-13,713
-12% -$84.6K ﹤0.01% 3042
2023
Q4 		$658K Sell
114,864
-17,558
-13% -$86.8K ﹤0.01% 2782
2023
Q3 		$633K Sell
132,422
-78,164
-37% -$485K ﹤0.01% 2739
2023
Q2 		$895K Buy
210,586
+156,204
+287% +$702K ﹤0.01% 2540
2023
Q1 		$289K Buy
+54,382
New +$339K ﹤0.01% 3263

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Raymond James & Associates's CRBU Position: Q3 2024 in Review

Raymond James & Associates reduced its Caribou Biosciences (CRBU) stake by 88% in Q3 2024, selling an estimated $166K and leaving 11,000 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

Raymond James & Associates first reported a position in CRBU in Q1 2023 and has held it in 7 quarters since. The position peaked at $895K in Q2 2023. 129 funds tracked by Wall St. Rank hold CRBU as of Q3 2024.

  • Raymond James & Associates held 11,000 shares of Caribou Biosciences worth $21.6K as of Q3 2024.
  • Raymond James & Associates sold 81,073 Caribou Biosciences shares in Q3 2024, an estimated $166K.
  • Caribou Biosciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3939 holding.
  • Raymond James & Associates first reported a position in Caribou Biosciences in Q1 2023 and has held it in 7 quarters since.
  • Raymond James & Associates's Caribou Biosciences position peaked at $895K in Q2 2023.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.